Ntla stock forecast.

Mar 3, 2022 · Intellia Therapeutics. Market Cap. $3B. Today's Change. (-1.23%) -$0.38. Current Price. $30.65. Price as of November 27, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ...

Ntla stock forecast. Things To Know About Ntla stock forecast.

According to 11 Wall Street analyst s that have issued a 1 year NTLA price target, the average NTLA price target is $77.46, with the highest NTLA stock price forecast at …Stock Price Forecast The 24 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 72.00, with a high estimate of 145.00 and a low estimate of 29.00.Discover historical prices for SAVA stock on Yahoo Finance. View daily, weekly or monthly format back to when Cassava Sciences, Inc. stock was issued.Real time Intellia Therapeutics (NTLA) stock price quote, stock graph, news & analysis.

View the latest Intellia Therapeutics Inc. (NTLA) stock price, news, historical charts, analyst ratings and financial information from WSJ.

The Vanguard Group, Inc. is the second largest shareholder owning 9.2% of common stock, and BlackRock, Inc. holds about 9.1% of the company stock. Furthermore, CEO John Leonard is the owner of 0.9 ...

NTLA Stock Forecast 2023, 2024, 2025 2023/11/18. Intellia Therapeutics stock predictions for next months and years. Intellia Therapeutics stock price …May 4, 2023 · As for financials, the company’s top line and bottom line beat Street forecasts while its cash, cash equivalents, and marketable securities stood at $1.2B at the end of the quarter compared to ... Intellia Therapeutics is a genome editing company that develops curative therapeutics for various diseases. The company's stock price, news, and analysis are shown on the web page, as well as its market cap, P/E ratio, dividend yield, and price target. The company has a consensus rating of Moderate Buy and a forecasted upside of 228.3%.Stock Price Forecast. The 24 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 72.00, with a high estimate of 145.00 and a low estimate of 29.00. The median estimate represents a +175.23% increase from the …Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...

Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings within the last quarter: These 12 analysts have an average price target of $77.5 versus the current price of Intellia ...

See Intellia Therapeutics, Inc. (NTLA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

May 4, 2023 · As for financials, the company’s top line and bottom line beat Street forecasts while its cash, cash equivalents, and marketable securities stood at $1.2B at the end of the quarter compared to ... Stock Price Forecast. The 25 analysts offering 12-month price forecasts for Gilead Sciences Inc have a median target of 90.10, with a high estimate of 116.00 and a low estimate of 71.00. The ...But Intellia has two programs in early-stage trials that could make this a monster stock in the future. NTLA-2001 is an in vivo gene-editing treatment for transthyretin amyloidosis, a condition ...Nov 30, 2023 · The average twelve-month price prediction for Intellia Therapeutics is $77.70 with a high price target of $136.00 and a low price target of $40.00. Learn more on NTLA's analyst rating history. Do Wall Street analysts like Intellia Therapeutics more than its competitors? Dec 1, 2023 · 2014. 598. John Leonard. https://www.intelliatx.com. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary ... Jun 8, 2023 · Here, I discuss the central investing thesis for its fellow CRISPR/Cas9 gene-editing specialist, Intellia Therapeutics (NTLA 2.54%). This biotech growth stock, too, stands out as a potential ...

Jun 13, 2023 · Intellia's Q1 2023 financial report shows a cash position of $1.2 billion, with collaboration revenue rising to $12.6 million and a net loss of $103.1 million. The success of NTLA-2002 in further ... Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance21 analysts have issued 1-year price objectives for Intellia Therapeutics' stock. Their NTLA share price targets range from $40.00 to $136.00. On average, they …Jul 1, 2021 · The stock price of Intellia Therapeutics (NASDAQ: NTLA), a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a solid 15% rise over the last five trading days ... Cathie Wood and Wall Street analysts aren't always on the same page. Analysts are bearish, for example, on the three stocks that have helped the most in Wood's Ark Innovation ETF (ARKK 1.26% ...The average Intellia Therapeutics stock forecast 2024 represents a -6.43% decrease from the last price of $30.8400001525879. For Intellia Therapeutics stock forecast for 2025, 12 predictions are offered for each month of 2025 with average Intellia Therapeutics stock forecast of $31.28, a high forecast of $34.48, and a low forecast …Stock Price Forecast The 24 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 72.00, with a high estimate of 145.00 and a low estimate of 29.00.

The average Editas Medicine stock forecast 2024 represents a 3.79% increase from the last price of $10.5299997329712. For Editas Medicine stock forecast for 2025, 12 predictions are offered for each month of 2025 with average Editas Medicine stock forecast of $10.98, a high forecast of $12.02, and a low forecast of $10.15.

Jul 6, 2023 · Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance That revenue goes along with positive earnings per share of $12.83 in 2022. And the forecast is that Vertex will grow earnings in 2023. What makes Vertex a potential high-growth biotech stock in ...February 6, 2023 at 9:35 AM · 6 min read. The tech-heavy Nasdaq represents a collection of more risky stocks than the other major indexes and that is reflected by a poorer performance in bear ...Nov 30, 2023 · According to 2 stock analysts, the average 12-month stock price forecast for DNA stock stock is $1.88, which predicts an increase of 45.74%. The lowest target is $1.25 and the highest is $2.50. On average, analysts rate DNA stock stock as a sell. Heading out for an outdoor adventure? Whether you’re planning a picnic, a hiking trip, or a beach day, one essential tool you need in your arsenal is a detailed weather 10 day forecast.Stock Price Forecast. The 25 analysts offering 12-month price forecasts for Gilead Sciences Inc have a median target of 90.10, with a high estimate of 116.00 and a low estimate of 71.00. The ...Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.NTNX one year forecast. Nutanix stock monthly and weekly forecasts. Skip to content. FORECST.COM 2023 – 2026 Stock Market Forecast NTNX stock forecast for 2023 – 2027. Last updated: November 16, 2023. Are you interested in Nutanix, Inc. stocks prediction? ... NTLA Stock Forecast; NTIP Stock Forecast;If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.

Stock Price Forecast The 24 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 72.00, with a high estimate of 145.00 and a low estimate of 29.00.

Jun 25, 2023 · But Intellia has two programs in early-stage trials that could make this a monster stock in the future. NTLA-2001 is an in vivo gene-editing treatment for transthyretin amyloidosis, a condition ...

Intellia Therapeutics Inc (NTLA) Stock Price & News - Google Finance Home NTLA • NASDAQ Intellia Therapeutics Inc Follow Share $30.93 After Hours: $31.14 (0.68%) …Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Analyst Forecast According to 21 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $77.4, which is an increase of 161.22% from the latest price.Aug 3, 2023 · Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to loss of $1.33 per share a year ago. The stock price of Intellia Therapeutics (NASDAQ: NTLA), a biotechnology company developing treatments using a CRISPR gene-editing system, has seen a solid 15% rise over the last five trading days ...What this means: InvestorsObserver gives Intellia Therapeutics Inc. (NTLA) an overall rank of 36, which is below average. Intellia Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 36 means that 64% of stocks appear more favorable to our system.Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings within the last quarter: These 12 analysts have an average price target of $77.5 versus the current price of Intellia ...Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE)Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023Plans to ...The stock is trading at $62.69 and its $108.64 indicates a 73% one-year gain lying ahead for NTLA. (See NTLA stock forecast on TipRanks)To find good ideas for stocks trading at attractive ...

The Intellia Therapeutics Inc stock price gained 2.54% on the last trading day (Friday, 24th Nov 2023), rising from $30.26 to $31.03. During the last trading day the stock fluctuated 5.87% from a day low at $30.13 to a day high of $31.90. The price has risen in 6 of the last 10 days and is up by 24.32% over the past 2 weeks.In the world of business, cash flow is king. Having a clear understanding of your company’s cash flow is essential for making informed financial decisions and ensuring the long-term success of your business.While many growth stocks have rallied in 2023, Exelixis stock has moved up and down since the start of the year. ... NTLA-2002 could be a game-changing treatment for hereditary angiodema (HAE), a ...Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo FinanceInstagram:https://instagram. best mortgage companies in azi m better insurancehow to get brics currencyflood insurance rate maps Dec 1, 2023 · View Intellia Therapeutics, Inc NTLA investment & stock information. Get the latest Intellia Therapeutics, Inc NTLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and... Stock Price Forecast. The 8 analysts offering 12-month price forecasts for Caribou Biosciences Inc have a median target of 23.00, with a high estimate of 30.00 and a low estimate of 13.00. The ... union bank phmark matson NTLA Stock 12 Months Forecast. Based on 19 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $78.65 with a high forecast of $136.00 and a low forecast of $31.00. The average price target represents a 151.68% change from the last price of $31.25. goos See Intellia Therapeutics, Inc. (NTLA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. The stock is selling for $100.49, and its $155.67 average price target is almost identical to Nowinski’s objective. (See Zscaler stock forecast ) Intellia Therapeutics ( NTLA )Even after rising 30% so far this year, shares of Intellia Therapeutics ( NTLA 4.88%) could easily experience another leg up if there's a bull market in the latter half of 2023. With positive ...